Achieving Additional Efficacy

Because trabodenoson is a novel mechanism that works through the trabecular meshwork, the primary fluid outflow path in the eye, we believe it could complement other existing mechanisms for the treatment of glaucoma. In fact, IOP lowering studies in preclinical models conducted by our team and collaborators have shown that IOP lowering is significantly improved when trabodenoson is combined with other glaucoma products, as compared to these products alone*.

*Presented at the 2014 ARVO Meeting (Association for Research in Vision and Ophthalmology). Session Title: Neurodegeneration and neuroprotection; Presentation Title: Evaluation of the neuroprotective effects of trabodenoson in a model of acute ocular hypertension.